MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00011-021-01445-2

Медицинская библиотека · Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021

Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.

Bahari Zahra, Jangravi Zohreh, Ghoshooni Hassan, Afarinesh Mohammad Reza, Meftahi Gholam Hossein

СтатьяОбзорПеревод в очереди

Аннотация

OBJECTIVE

Coronavirus disease 2019 (COVID-19) is a world-wide pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, treatment of severe COVID-19 is far from clear. Therefore, it is urgent to develop an effective option for the treatment of patients with COVID-19. Most patients with severe COVID-19 exhibit markedly increased serum levels of pro-inflammatory cytokines, including interferon (IFN)-α, IFN-γ, and interleukin (IL)-1β. Immunotherapeutic strategies have an important role in the suppression of cytokine storm and respiratory failure in patients with COVID-19.

METHODS

A systematic search in the literature was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, as well as Google Scholar preprint database using all available MeSH terms for Coronavirus, SARS-CoV-2, anti-rheumatoid agents, COVID-19, cytokine storm, immunotherapeutic drugs, IFN, interleukin, JAK/STAT inhibitors, MCP, MIP, TNF.

RESULTS

Here, we first review common complications of COVID-19 patients, particularly neurological symptoms. We next explain host immune responses against COVID-19 particles. Finally, we summarize the existing experimental and clinical immunotherapeutic strategies, particularly anti-rheumatoid agents and also plasma (with a high level of gamma globulin) therapy for severe COVID-19 patients. We discuss both their therapeutic effects and side effects that should be taken into consideration for their clinical application.

CONCLUSION

It is suggested that immunosuppressants, such as anti-rheumatoid drugs, could be considered as a potential approach for the treatment of cytokine storm in severe cases of COVID-19. One possible limitation of immunosuppressant therapy is their inhibitory effects on host anti-viral immune response. So, the appropriate timing of administration should be carefully considered.

Для цитирования: Bahari Zahra, Jangravi Zohreh, Ghoshooni Hassan, Afarinesh Mohammad Reza, Meftahi Gholam Hossein. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.. Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 2021. DOI: 10.1007/s00011-021-01445-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.